Benzinga

Benzinga

Benzinga

viernes, septiembre 04

Regeneron Pharmaceuticals Inc

REGNNASDAQ
Trade with Public
Trade with Public
$843.47
-8.56-1%
al cierre: Sep 2, 5:00 PM EST
$853.20
1.170.14%
Premercado: 7:04 AM EST
Panorámica generalNoticiasPrevisión de beneficiosEventosPrecios objetivoFinanzasSentimientoPropiedadDividendosCompararOpcionesInforme de acciones

Regeneron Pharmaceuticals Analyst Price Targets

Wall Street analyst price targets and consensus rating for Regeneron Pharmaceuticals (REGN).

Price Target Range — 6 Quarters

Analyst Consensus — 23 Analysts

17Buy
6Hold
Consensus RatingBuy# Analysts23Avg. Consensus PT$797Upside to Avg. PT-6.6%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 17, 2026Leerink PartnersDavid RisingerPT RaiseMarket Perform$641→$824
Aug 3, 2026CitigroupGeoff MeachamPT RaiseNeutral$700→$740
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Citigroup Maintains Neutral on Regeneron Pharmaceuticals, Raises Price Target to $740

Citigroup analyst Geoff Meacham maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Neutral and raises the price target from $700 to $740.
Benzinga Newsdesk

PRO
Guggenheim Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $1030

Guggenheim analyst Brad Canino maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $1000 to $1030.
Benzinga Newsdesk

PRO
RBC Capital Maintains Sector Perform on Regeneron Pharmaceuticals, Raises Price Target to $737

RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $696 to $737.
Benzinga Newsdesk

PRO
Morgan Stanley Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $758

Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $730 to $758.
Benzinga Newsdesk

PRO
Cantor Fitzgerald Maintains Overweight on Regeneron Pharmaceuticals, Raises Price Target to $795

Cantor Fitzgerald analyst Carter Gould maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Overweight and raises the price target from $750 to $795.
Benzinga Newsdesk

PRO
Wells Fargo Maintains Equal-Weight on Regeneron Pharmaceuticals, Raises Price Target to $750

Wells Fargo analyst Mohit Bansal maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $700 to $750.
Benzinga Newsdesk

Datos y APIs: APIs de Benzinga · API de noticias de acciones · API de calificaciones de analistas · API de logotipos de empresas

Datos de mercado proporcionados por APIs de Benzinga

Benzinga

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL

© 2026 Benzinga | All Rights Reserved